OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
OKYO is trading near its 52-week low of $1.265 (15% above the low) on light trading volume (0.1× avg).
Summary
OKYO Pharma announced first patients enrolled in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain, a condition with no approved treatment. The trial is now active at its first U.S. site with additional sites planned across the U.S. and Europe.
Key Events · Product Development and Regulatory · OKYO
-
First Patients Enrolled in Phase 3 NEPTUNE Trial
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP), a condition with no FDA-approved therapy. First site activated at Toyos Clinic in Nashville, TN by Dr. Melissa Toyos.
-
Registrational Trial Design
NEPTUNE is a multicenter registrational study per FDA guidance. Patients receive 4 drops per day for 12 weeks. Primary endpoint is change from baseline in ocular pain VAS score; secondary endpoints include Quality-of-Life scores and in-vivo confocal microscopy findings.
-
Global Site Expansion Underway
Enrollment will occur at multiple clinical sites across the United States and Europe, including Italy, Spain, and France. Additional U.S. sites are being activated.
-
First-in-Class Opportunity
Urcosimod is a first-in-class lipid-conjugated chemerin peptide agonist of ChemR23 with dual ocular analgesic and anti-inflammatory activity. No FDA-approved treatment exists for NCP, representing significant unmet medical need.
Analysis · OKYO · Life Sciences
OKYO Pharma has begun enrolling patients in its Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP), a condition with no FDA-approved therapy. This is the company's lead clinical program and the first registrational study for a potential first-in-class treatment. The milestone de-risks the program by confirming trial activation and patient enrollment, and it comes at a critical time — the company reported only $20.6M in cash as of March 2026 and has an existing $50M ATM program to fund operations. Successful Phase 3 execution is the primary value driver for the stock.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OKYO was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.1M. The 52-week trading range was $1.26 to $3.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.